Transforming growth factor beta receptor II fusion polypeptides
AssigneeAccleron Pharma Inc.
InventorsRavindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
Life of this patent
Estimating the term…
Abstract
In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of TβRII polypeptide useful to selectively antagonize a TβRII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGFβ associated disorders.
Claims9
A Transforming Growth Factor β Receptor II (TβRII) fusion polypeptide comprising a first amino acid sequence from the extracellular domain of TβRII and a heterologous amino acid sequence, wherein the first amino acid sequence consists of an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:
- 13,
- wherein the fusion polypeptide does not include the amino acids corresponding to amino acids 1-22 and 185-592 of SEQ ID NO:
- 6;
- and wherein the fusion polypeptide binds Transforming Growth Factor β1 or Transforming Growth Factor β3.
Dependencies are inferred from the claim text.